Cargando…

Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus

Oncolytic viruses (OVs) can specifically replicate in the host and cause cancer cell lysis while inducing an antitumor immune response. The aim of this study is to investigate the impact of either pre-existing immunity against herpes simplex virus type-1 (HSV-1) or multicycle treatment with OVs on a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Jun, Murad, Yanal M., Sun, Yi, Lee, I-Fang, Samudio, Ismael, Liu, Xiaohu, Jia, William Wei-Guo, Zhao, Ronghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693100/ https://www.ncbi.nlm.nih.gov/pubmed/36366425 http://dx.doi.org/10.3390/v14112327

Ejemplares similares

Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes
por: Chouljenko, Dmitry V., et al.
Publicado: (2020)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1
por: Chouljenko, Dmitry V., et al.
Publicado: (2023)

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
por: Hoang, Huy-Dung, et al.
Publicado: (2023)

Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: The key to breaking the log jam?
por: Li, Yuwei, et al.
Publicado: (2020)

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
por: Tang, Tianyu, et al.
Publicado: (2022)

VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes
por: Shen, Yinan, et al.
Publicado: (2022)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
por: Kangas, Chase, et al.
Publicado: (2021)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Immune System Stimulation by Oncolytic Rodent Protoparvoviruses
por: Angelova, Assia, et al.
Publicado: (2019)

Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host’s Innate Antiviral Immunity to Attack Tumor Cells
por: Fu, Xinping, et al.
Publicado: (2020)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
por: Jahan, Nusrat, et al.
Publicado: (2021)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host
por: Guo, Z. Sheng, et al.
Publicado: (2010)

Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability
por: Howard, Faith, et al.
Publicado: (2022)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus
por: Ono, Ryosuke, et al.
Publicado: (2022)

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2013)

The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
por: Tang, Guijin, et al.
Publicado: (2023)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

Complementary Medicine for Stimulation of Anticancer Immunity
por: An, Hyo-Jin, et al.
Publicado: (2019)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

Oncolytic Viruses as Anticancer Vaccines
por: Woller, Norman, et al.
Publicado: (2014)

EPCT-22 SAFETY AND EFFICACY OF INTRAVENTRICULAR IMMUNOVIROTHERAPY WITH ONCOLYTIC HSV-1 G207 FOR TREATMENT OF LEPTOMENINGEAL DISEASE
por: Kang, Kyung-Don, et al.
Publicado: (2021)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity
por: Leng, Qibin, et al.
Publicado: (2020)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles
por: Fu, Xinping, et al.
Publicado: (2018)

Chimeric HCMV/HSV-1 and Δγ(1)34.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory()()
por: Ghonime, Mohammed G., et al.
Publicado: (2017)

Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
por: Koch, Marilin S., et al.
Publicado: (2020)

Pre-existing immunity against vaccine vectors – friend or foe?
por: Saxena, Manvendra, et al.
Publicado: (2013)

Strategy to detect pre-existing immunity to AAV gene therapy
por: Falese, L, et al.
Publicado: (2017)

Pre-existing immunity modulates responses to mRNA boosters
por: Dangi, Tanushree, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1vf3ku1324ajrm88t6os9nih3q